Published in Br J Cancer on June 29, 2010
Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.83
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila) (2012) 1.49
A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) (2012) 1.21
Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer (2012) 1.07
The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev (2014) 0.83
Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients. Mol Cancer (2014) 0.81
Updates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemoprevention. Cancers (Basel) (2014) 0.79
Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Med (2017) 0.75
Lung cancer screening with low-dose computed tomography. Radiol Clin North Am (2014) 0.75
Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. Sci Rep (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology (1983) 30.77
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Genetic risk prediction--are we there yet? N Engl J Med (2009) 7.30
Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med (2000) 6.90
Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet (2005) 6.63
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med (2006) 4.48
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet (2009) 4.22
Prediction of colorectal cancer by a patient consultation questionnaire and scoring system: a prospective study. Lancet (2002) 3.95
The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer (2007) 3.15
Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat (2005) 2.53
The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med (2007) 2.34
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol (2006) 2.05
Risk factors and individual probabilities of melanoma for whites. J Clin Oncol (2005) 1.65
Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol (1994) 1.59
Displaying clinical data relationships using scaled rectangle diagrams. Stat Med (2001) 1.53
Lung cancer risk prediction: a tool for early detection. Int J Cancer (2007) 1.51
Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev (1996) 1.43
Selecting patients for randomized trials: a systematic approach based on risk group. Trials (2006) 1.33
Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol (2007) 1.30
Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst (2001) 1.21
Second hand smoke, age of exposure and lung cancer risk. Lung Cancer (2008) 1.19
Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epidemiol (2003) 1.05
A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States) Cancer Causes Control (1997) 0.96
Scaled rectangle diagrams can be used to visualize clinical and epidemiological data. J Clin Epidemiol (2005) 0.93
Cardiovascular risk can be represented by scaled rectangle diagrams. J Clin Epidemiol (2009) 0.91
Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. Epidemiology (2003) 0.90
Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer. Expert Rev Anticancer Ther (2009) 0.78
Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer (2001) 6.16
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health (1989) 5.20
Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am (1992) 4.34
Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr (1994) 4.32
Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int J Epidemiol (1997) 3.79
Breast cancer treatment and natural history: new insights from results of screening. Lancet (1992) 3.77
A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet (2000) 3.76
The natural history of breast carcinoma: what have we learned from screening? Cancer (1999) 3.55
Dietary effects on breast-cancer risk in Singapore. Lancet (1991) 3.32
Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer (1995) 3.32
The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am (2000) 3.18
The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer (2007) 3.15
Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr (2001) 2.97
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (1997) 2.75
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen (2004) 2.62
Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer (1990) 2.61
Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut (1983) 2.53
Early onset of breast cancer in a group of British black women. Br J Cancer (2008) 2.47
Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer (1995) 2.47
Dietary isoflavones: biological effects and relevance to human health. J Nutr (1999) 2.45
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer (2003) 2.26
Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-hour dietary recall cohort. Eur J Clin Nutr (2012) 2.08
Validation of weighed records and other methods of dietary assessment using the 24 h urine nitrogen technique and other biological markers. Br J Nutr (1995) 2.07
Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol (2006) 2.02
Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis. Hum Reprod Update (2009) 1.99
Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.98
Infiltrating lobular carcinoma of the breast. Histopathology (1982) 1.98
Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ (1999) 1.96
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer (2006) 1.84
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen (2004) 1.81
A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. Acta Radiol (2007) 1.80
Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol (1987) 1.79
Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology (2012) 1.72
Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev (1999) 1.72
Lung carcinoma in former smokers. Cancer (1996) 1.70
Effect of breast cancer screening after age 65. J Med Screen (1995) 1.69
UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax (2011) 1.62
Multi-state Markov models in cancer screening evaluation: a brief review and case study. Stat Methods Med Res (2010) 1.60
Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis (1995) 1.57
Pickled vegetables in the aetiology of oesophageal cancer in Hong Kong Chinese. Lancet (1992) 1.56
Comparison of single reading with double reading of mammograms, and change in effectiveness with experience. Br J Radiol (1995) 1.54
Evolutionary evidence of the effect of rare variants on disease etiology. Clin Genet (2010) 1.54
Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. Am J Epidemiol (1998) 1.54
Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res (1999) 1.53
Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. Br J Surg (2000) 1.51
Correction of risk estimates for measurement error in epidemiology. Methods Inf Med (1995) 1.50
Factors related to cervicitis in Qashghaee nomadic women of southern Iran. Rev Epidemiol Sante Publique (1997) 1.49
Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). Int J Epidemiol (1991) 1.49
Repeat measurement of case-control data: correcting risk estimates for misclassification due to regression dilution of lipids in transient ischemic attacks and minor ischemic strokes. Am J Epidemiol (1991) 1.47
Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer (1997) 1.46
Reduced DNA repair capacity in lung cancer patients. Cancer Res (1996) 1.44
Breast cancer in Singapore: trends in incidence 1968-1992. Int J Epidemiol (1996) 1.41
Major conceptual change required to improve lung cancer: see a respiratory physician. Eur Respir J (2003) 1.40
K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem (2000) 1.40
A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg (2008) 1.40
Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology. Br J Cancer (2003) 1.40
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res (2001) 1.40
Excess leukemia and multiple myeloma in a mining county in northeast Texas. Tex Med (1994) 1.39
Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer (2000) 1.37
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Meta-analysis by combining p-values: simulated linkage studies. Genet Epidemiol (1999) 1.36
Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer (2008) 1.35
Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer (1997) 1.32
Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics (2000) 1.32
Number needed to screen: lives saved over 20 years of follow-up in mammographic screening. J Med Screen (2004) 1.31
Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys (1989) 1.30
Reactive airways dysfunction after exposure to teargas. Lancet (1992) 1.30
Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol (2000) 1.30
Lung cancer screening: the way forward. Br J Cancer (2008) 1.28
Risk of breast cancer in relation to reproductive factors in Denmark. Br J Cancer (1988) 1.28
Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev (1998) 1.28
Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer Causes Control (1992) 1.27
Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer (1996) 1.26
Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis (2000) 1.26
Mammographic parenchymal patterns and risk of breast cancer at and after a prevalence screen in Singaporean women. Int J Epidemiol (2000) 1.25
Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis (1999) 1.25
XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis (2000) 1.25
The Liverpool Lung Project research protocol. Int J Oncol (2005) 1.23
Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer (2009) 1.23
Management of menorrhagia: an audit of practices in the Anglia menorrhagia education study. BMJ (2001) 1.23
Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol (2009) 1.22
An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res (2001) 1.21
A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality. Br J Cancer (2007) 1.20
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer (2010) 1.19
The long-term benefits of a single scan for abdominal aortic aneurysm (AAA) at age 65. Eur J Vasc Endovasc Surg (2001) 1.18
Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer (1998) 1.18
The development of breast carcinoma in women with thyroid carcinoma. Cancer (2001) 1.17
Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme 1990-96. Br J Cancer (2002) 1.16
Serum regulation of the estrogen responsiveness of the human breast cancer cell line MCF-7. Cancer Res (1983) 1.15
Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin Chim Acta (1997) 1.14
Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis (1995) 1.13
A new era in the diagnosis of breast cancer. Surg Oncol Clin N Am (2000) 1.12